{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:59:51Z","timestamp":1791475191540,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011958","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","award":["8020-00176B"],"award-info":[{"award-number":["8020-00176B"]}],"id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jaad.2019.05.055","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T11:20:59Z","timestamp":1559042459000},"page":"326-335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Use of antiepileptic drugs and risk of skin cancer: A nationwide case-control study"],"prefix":"10.1016","volume":"82","author":[{"given":"Kasper Bruun","family":"Kristensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidsel Arnspang","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun Alba Johannesdottir","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Potteg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9715","key":"10.1016\/j.jaad.2019.05.055_bib1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0140-6736(09)61196-X","article-title":"Non-melanoma skin cancer","volume":"375","author":"Madan","year":"2010","journal-title":"The Lancet"},{"issue":"19","key":"10.1016\/j.jaad.2019.05.055_bib2","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1200\/JCO.2006.06.1325","article-title":"Anatomic site, sun exposure, and risk of cutaneous melanoma","volume":"24","author":"Whiteman","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.jaad.2019.05.055_bib3","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM198405033101805","article-title":"Cutaneous squamous-cell carcinoma in patients treated with PUVA","volume":"310","author":"Stern","year":"1984","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jaad.2019.05.055_bib4","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/joim.12629","article-title":"Hydrochlorothiazide use is strongly associated with risk of lip cancer","volume":"282","author":"Potteg\u00e5rd","year":"2017","journal-title":"J Intern Med"},{"issue":"4","key":"10.1016\/j.jaad.2019.05.055_bib5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jaad.2017.11.042","article-title":"Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark","volume":"78","author":"Pedersen","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.05.055_bib6","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaad.2018.06.014","article-title":"Hydrochlorothiazide use and risk of Merkel cell carcinoma and malignant adnexal skin tumors: a nationwide case-control study","volume":"80","author":"Pedersen","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2019.05.055_bib7","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/jamainternmed.2018.1652","article-title":"Association of hydrochlorothiazide use and risk of malignant melanoma","volume":"178","author":"Potteg\u00e5rd","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jaad.2019.05.055_bib8","author":"Shear"},{"issue":"11","key":"10.1016\/j.jaad.2019.05.055_bib9","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1158\/1055-9965.EPI-10-0652","article-title":"Photosensitizing medication use and risk of skin cancer","volume":"19","author":"Kaae","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1016\/j.jaad.2019.05.055_bib10","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/ijc.28396","article-title":"Epilepsy, anti-epileptic medication use and risk of cancer: epilepsy, anti-epileptic medication use and risk of cancer","volume":"134","author":"Kaae","year":"2014","journal-title":"Int J Cancer"},{"issue":"7 Suppl","key":"10.1016\/j.jaad.2019.05.055_bib11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/1403494810393562","article-title":"The Danish cancer registry","volume":"39","author":"Gjerstorff","year":"2011","journal-title":"Scand J Public Health"},{"issue":"3","key":"10.1016\/j.jaad.2019.05.055_bib12","article-title":"Data resource profile: the Danish National Prescription Registry","volume":"46","author":"Potteg\u00e5rd","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jaad.2019.05.055_bib13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol November"},{"issue":"8","key":"10.1016\/j.jaad.2019.05.055_bib14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","article-title":"The Danish Civil Registration System as a tool in epidemiology","volume":"29","author":"Schmidt","year":"2014","journal-title":"Eur J Epidemiol"},{"issue":"7 Suppl","key":"10.1016\/j.jaad.2019.05.055_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/1403494810394715","article-title":"Danish Education Registers","volume":"39","author":"Jensen","year":"2011","journal-title":"Scand J Public Health"},{"issue":"3","key":"10.1016\/j.jaad.2019.05.055_bib16","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/EDE.0000000000000802","article-title":"Melanoma of the skin in the Danish Cancer Registry and the Danish Melanoma Database: a validation study","volume":"29","author":"Pedersen","year":"2018","journal-title":"Epidemiology"},{"issue":"5","key":"10.1016\/j.jaad.2019.05.055_bib17","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.cdp.2007.04.011","article-title":"Do incident and new subsequent cases of non-melanoma skin cancer registered in a Danish prospective cohort study have different 10-year mortality?","volume":"31","author":"Jensen","year":"2007","journal-title":"Cancer Detect Prev"},{"key":"10.1016\/j.jaad.2019.05.055_bib18","series-title":"International Classification of Diseases","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.jaad.2019.05.055_bib19","series-title":"International Classification of Diseases for Oncology","author":"World Health Organization","year":"2000"},{"key":"10.1016\/j.jaad.2019.05.055_bib20","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2018. Available at: https:\/\/www.whocc.no\/atc_ddd_index_and_guidelines\/guidelines\/. Accessed January 30, 2019."},{"key":"10.1016\/j.jaad.2019.05.055_bib21","author":"GlaxoSmithKline"},{"key":"10.1016\/j.jaad.2019.05.055_bib22","series-title":"Tegretol: full prescribing information","year":"2015"},{"issue":"5","key":"10.1016\/j.jaad.2019.05.055_bib25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2165\/00002018-200225050-00004","article-title":"Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management","volume":"25","author":"Moore","year":"2002","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.jaad.2019.05.055_bib26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00023210-199912030-00005","article-title":"Anticonvulsant-induced cutaneous reactions: incidence, mechanisms and management","volume":"12","author":"Ruble","year":"1999","journal-title":"CNS Drugs"},{"issue":"10","key":"10.1016\/j.jaad.2019.05.055_bib27","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2165\/11592780-000000000-00000","article-title":"Drug-induced photosensitivity: culprit drugs, management and prevention","volume":"34","author":"Drucker","year":"2011","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.055_bib28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.clindermatol.2011.11.014","article-title":"Psychiatric medications: adverse cutaneous drug reactions","volume":"31","author":"Bliss","year":"2013","journal-title":"Clin Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2019.05.055_bib29","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/j.1600-0625.2008.00733.x","article-title":"Photocarcinogenesis of topical tazarotene and isotretinoin alone and in combination with valproic acid in hairless mice","volume":"17","author":"Lerche","year":"2008","journal-title":"Exp Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.05.055_bib30","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1600-0536.1986.tb01356.x","article-title":"Patch test diagnosis in carbamazepine erythroderma","volume":"15","author":"Silva","year":"1986","journal-title":"Contact Dermatitis"},{"issue":"5","key":"10.1016\/j.jaad.2019.05.055_bib31","first-page":"206","article-title":"Photosensitive lichenoid reaction accompanied by nonphotosensitive subacute prurigo caused by carbamazepine","volume":"5","author":"Yasuda","year":"1988","journal-title":"Photodermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.05.055_bib32","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1600-0536.1989.tb03142.x","article-title":"Eczematous drug eruption from carbamazepine: coexistence of contact and photocontact sensitivity","volume":"20","author":"Terui","year":"1989","journal-title":"Contact Dermatitis"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.055_bib33","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s11095-005-8497-9","article-title":"Analytical studies on the prediction of photosensitive\/phototoxic potential of pharmaceutical substances","volume":"23","author":"Onoue","year":"2006","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.jaad.2019.05.055_bib34","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1751-1097.2009.00590.x","article-title":"Photochemical reactions involved in the phototoxicity of the anticonvulsant and antidepressant drug Lamotrigine (Lamictal\u00ae)","volume":"85","author":"Bilski","year":"2009","journal-title":"Photochem Photobiol"},{"issue":"2","key":"10.1016\/j.jaad.2019.05.055_bib35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/pds.4145","article-title":"New use of prescription drugs prior to a cancer diagnosis","volume":"26","author":"Pottegard","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.jaad.2019.05.055_bib36","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/bcpt.12946","article-title":"Considerations for pharmacoepidemiological studies of drug-cancer associations","volume":"122","author":"Potteg\u00e5rd","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"8","key":"10.1016\/j.jaad.2019.05.055_bib37","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/jdv.12921","article-title":"Use of antihypertensive drugs and risk of skin cancer","volume":"29","author":"Schmidt","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.jaad.2019.05.055_bib38","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/jid.2013.33","article-title":"Photosensitizing agents and the risk of non-melanoma skin cancer: a population-based case\u2013control study","volume":"133","author":"Robinson","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.05.055_bib39","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jaad.2017.11.042","article-title":"Hydrochlorothiazide use and risk of non-melanoma skin cancer: a nationwide case-control study from Denmark","volume":"78","author":"Arnspang","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2019.05.055_bib40","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/pds.3635","article-title":"Measures of 'exposure needed for one additional patient to be harmed' in population-based case-control studies","volume":"23","author":"Hallas","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.jaad.2019.05.055_bib41","first-page":"V07160465","article-title":"Benzodiazepines should still be first-line treatment for alcohol withdrawal","volume":"179","author":"Askgaard","year":"2017","journal-title":"Ugeskr Laeger"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221930859X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221930859X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:53:20Z","timestamp":1759272800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096221930859X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S019096221930859X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.05.055","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of antiepileptic drugs and risk of skin cancer: A nationwide case-control study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.05.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}